Aspen Neuroscience, Inc. priced its initial public offering at $15.00 a share, offering 9,375,000 shares of common stock, to list on the Nasdaq Global Select Market under the symbol ASPE. It filed a Form S-1 registration statement for an initial public offering on October 9, 2026. As of November 4, 2026, its final prospectus is on file (Form 424B4, October 30, 2026).
Sell to companies like Aspen Neuroscience, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
Aspen Neuroscience, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-10-09. It has amended it 2 times. It filed its final prospectus on 2026-10-30, at a public offering price of $15.00 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our common stock has been approved for listing on the Nasdaq Global Select Market under the symbol “ASPE.”From the 424B4 filed 2026-10-30
Shares offered
This is the initial public offering of shares of common stock by Aspen Neuroscience, Inc. We are offering 9,375,000 shares of our common stock.From the 424B4 filed 2026-10-30
Offering price
The initial public offering price is $15.00 per share .From the 424B4 filed 2026-10-30
Use of proceeds
We currently intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, to fund the clinical development of sasineprocel, including the ongoing Phase 1/2a ASPIRO trial and the initiation of a Phase 3 trial in sporadic and genetic PD, to fund the research and development of our other product candidates and for working capital and general corporate purposes.From the 424B4 filed 2026-10-30
Net loss or income
Unaudited pro forma net loss for the year ended December 31, 2025 includes estimated non-cash stock-based compensation expense of approximately $1.8 million resulting from the Note Forgiveness, which we expect to recognize in our historical results in the third quarter of 2026, and such expense is not reflected in unaudited pro forma net loss for the six months ended June 30, 2026.From the S-1/A filed 2026-10-26
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2026-10-09 | Registration statement filed | S-1 |
| 2026-10-22 | Registration statement amended | S-1/A |
| 2026-10-26 | Registration statement amended | S-1/A |
| 2026-10-30 | Final prospectus filed: the offering is priced | 424B4 |
Check before you invest in Aspen Neuroscience, Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Aspen Neuroscience, Inc. and the records around it.
Also filing to list on the Nasdaq Global Select Market
IPO filings on the Nasdaq Global Select Market in Q4 2026, newest first.
- Anthropic, PBC (Nov 2026)
- Iambic Therapeutics, Inc. (Oct 2026)
Watch Aspen Neuroscience, Inc.
Get an email when Aspen Neuroscience, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Aspen Neuroscience, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Aspen Neuroscience, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aspen Neuroscience, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Tools for this story
Each opens in a new tab, filled in for Aspen Neuroscience, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.